Nektar Therapeutics (NASDAQ:NKTR) Insider Mark Andrew Wilson Sells 676 Shares

Nektar Therapeutics insider Mark Andrew Wilson sold 676 shares at $26.59 each, totaling $17,974.84, resulting in a 3.22% decrease in his ownership. Post-sale, he holds 20,312 shares valued at $540,096.08. The transaction was disclosed to the SEC. Nektar's stock opened at $28.00, with a market cap of $532.56 million and a P/E ratio of -3.18. The company reported a quarterly EPS of ($2.95), exceeding estimates, and had revenue of $11.18 million. Analysts have set a moderate buy rating with an average target price of $88.33.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Mark Andrew Wilson sold 676 shares of the business's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $26.59, for a total value of $17,974.84. Following the sale, the insider owned 20,312 shares in the company, valued at $540,096.08. The trade was a 3.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Nektar Therapeutics Stock Performance

3 Bullish Biotech Stocks With Explosive Growth Trends

Shares of NKTR stock opened at $28.00 on Friday. Nektar Therapeutics has a fifty-two week low of $6.45 and a fifty-two week high of $37.38. The firm has a market capitalization of $532.56 million, a price-to-earnings ratio of -3.18 and a beta of 0.95. The stock's 50-day simple moving average is $22.50 and its 200-day simple moving average is $14.96.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($2.95) EPS for the quarter, topping analysts' consensus estimates of ($3.13) by $0.18. Nektar Therapeutics had a negative return on equity of 631.43% and a negative net margin of 163.17%.The firm had revenue of $11.18 million during the quarter, compared to the consensus estimate of $9.42 million. As a group, equities analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current year.

Hedge Funds Weigh In On Nektar Therapeutics

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

Several hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in Nektar Therapeutics by 29.5% in the 4th quarter. JPMorgan Chase & Co. now owns 1,182,995 shares of the biopharmaceutical company's stock valued at $1,100,000 after purchasing an additional 269,695 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Nektar Therapeutics by 26.5% in the 4th quarter. Wells Fargo & Company MN now owns 108,975 shares of the biopharmaceutical company's stock valued at $101,000 after acquiring an additional 22,822 shares during the last quarter. Renaissance Technologies LLC grew its stake in Nektar Therapeutics by 17.5% during the 4th quarter. Renaissance Technologies LLC now owns 3,910,786 shares of the biopharmaceutical company's stock worth $3,637,000 after buying an additional 583,153 shares during the last quarter. XTX Topco Ltd grew its stake in Nektar Therapeutics by 595.8% during the 4th quarter. XTX Topco Ltd now owns 244,701 shares of the biopharmaceutical company's stock worth $228,000 after buying an additional 209,531 shares during the last quarter. Finally, Harvest Investment Services LLC acquired a new stake in Nektar Therapeutics during the 4th quarter worth approximately $27,000. Institutional investors and hedge funds own 75.88% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. BTIG Research boosted their price target on Nektar Therapeutics from $60.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, June 24th. B. Riley boosted their price target on Nektar Therapeutics from $60.00 to $85.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. William Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a report on Monday, May 12th. HC Wainwright boosted their price objective on Nektar Therapeutics to $120.00 and gave the company a "buy" rating in a research report on Tuesday, June 24th. Finally, Wall Street Zen cut Nektar Therapeutics from a "hold" rating to a "sell" rating in a research report on Wednesday, May 14th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $88.33.

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

Check Out Our Latest Analysis on NKTR

About Nektar Therapeutics

(Get Free Report)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.